Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Sinucare Natural Health Care Corporation has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action involves a single distinct examiner and 1 distinct art unit. This singular focus suggests that the company is currently pursuing a specific advancement in natural health or biotechnology through a single patent application. The concentration within one art unit indicates that the filing is being reviewed by a group specialized in pharmaceutical or biological compositions.
SUSAN COE HOFFMAN is the busiest examiner for the company, with the pending office action. This represents the total pending workload for the portfolio. Because the entire prosecution effort is concentrated under one examiner and one art unit, the company's immediate success is tied to a single point of review. This centralization allows for a focused strategy in responding to the office but also means the company's current experience is limited to one examiner's interpretation of biotechnology standards. Practitioners should prioritize a clear and data-supported response to this examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOFFMAN, SUSAN COE | 1 | 54.2% | +25.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18661370 | INTRANASAL COMPOSITION AND METHOD | HOFFMAN, SUSAN COE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18661370 | INTRANASAL COMPOSITION AND METHOD | HOFFMAN, SUSAN COE | — |
| Art Unit | Apps |
|---|---|
| 1655 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18661370 | INTRANASAL COMPOSITION AND METHOD | HOFFMAN, SUSAN COE | 1655 | §101§103 | Non-Final OA | — | Pending | May 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial